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Abbreviations 
AJCC  American Joint Committee on Cancer 
APR  Abdominoperineal resection       
CC   Colon cancer 
CI  Confidence interval 
CIN  Chromosomal instability 
CRM  Circumferential resection margin 
CRN   Cancer Registry of Norway 
CRT  Chemoradiotherapy 
CT  Computer tomography 
CRC  Colorectal cancer 
CEA  Carcinoembryonic antigen 
LN   Lymph nodes 
LR  Local recurrence 
MDT  Multidisciplinary team 
MRI  Magnetic resonance imaging 
MSI  Microsatellite instability 
NCCR Norwegian Colorectal Cancer Registry 
PET  Positron emission tomography 
R0  No residual disease 
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R1  Microscopic residual disease 
R2  Macroscopic residual disease 
TNM  Tumour-node-metastasis 
TME  Total mesorectal excision 
UICC Union for International Cancer Control 
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1. Summary 
1.1 Background 
Since the early 1990s, there has been increased attention on the management of 
patients with rectal cancer, both in Norway and in many other countries. The 
Norwegian Rectal Cancer Registry, which was established in 1994, provides 
feedback regarding patient outcomes to all hospitals involved in rectal cancer surgery. 
A new operative technique, total mesorectal excision or TME, was introduced at the 
same time, and pre-operative radiotherapy was introduced as part of the primary 
treatment. Eventually, several low-volume hospitals discontinued surgery for rectal 
cancer.  
With regard to colon cancer, adjuvant chemotherapy for patients with lymph node 
metastases was introduced in 1997. No other systematic changes in colon cancer 
treatment took place until 2007, when a national Colon Cancer Registry was 
established. The Norwegian Colorectal Cancer Registry was established by 
combining these two registries. 
1.2 Purpose of the study 
We wished to investigate the consequences of implementing national guidelines with 
a strong focus on rectal cancer as compared to colon cancer during the time period of 
1994 to 2003. In particular, we aimed to compare short- and long-term survival at the 
national level. In addition, we wanted to investigate lymph node harvest in colon 
cancer patients in Norway, as this has been suggested to be a quality indicator in 
colon cancer surgery.  
1.3 Materials and methods 
Data were provided by the Cancer Registry of Norway and by the Norwegian Rectal 
Cancer Registry for Paper I and Paper II. For Paper III, the new Colorectal Cancer 
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Registry, which was established in 2007, provided the data. Using these data in 
combination with mortality data from Statistics Norway, we compared relative 
survival for colon and rectal cancer in different time periods and excess mortality in 
colon and rectal cancer at various time intervals during the five-year period after 
treatment. For Paper III, we identified colon cancer patients who were curatively 
resected in 2007 and 2008. We studied variables that might be indicative of poor (i.e. 
<9) lymph node harvest and identified patients with lymph node positive disease. 
1.4 Results 
We found no difference in survival between colon and rectal cancer in the time period 
1994–1996. However, rectal cancer showed significantly better survival than colon 
cancer in 2001–2003. Most patient groups showed increased survival between the 
1994-1996 timeperiod to the 2001-2003 timeperiod; the exception was colon cancer 
patients >75 years of age with lymph node metastasis. Rectal cancer patients had 
lower short-term mortality than colon cancer patients. By about four years after 
primary surgery, rectal cancer patients had a higher mortality than colon cancer 
patients. 
We found the following factors to be associated with poor lymph node harvest, which 
has been proposed as an indicator of poor-quality treatment: being elderly, being 
male, having sigmoid cancer and the presence of a short distal margin. However, 
none of these factors was significant when it came to identifying patients with 
positive lymph nodes. 
1.5 Conclusion 
After the introduction of national treatment guidelines, the survival of rectal cancer 
patients surpassed the survival of colon cancer patients. Short-term mortality was 
lower in rectal cancer patients, and 5-year survival was higher than for colon cancer. 
There is a need for an increased focus on colon cancer patients, and in particular on 
patients > 75 years of age with lymph node positive disease. 
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3. Introduction 
3.1 History 
Cancer has been observed in dinosaur samples from 200 million years ago and seems 
to be inherently associated with life.1 Osteosarcoma and metastatic disease has been 
found in mummified bodies from the Middle East and South America. The first 
recorded dissections of humans took place about 500 BC, and Hippocrates (460–377 
BC) was the first to recognise cancer as a distinctive disease with both local and 
distant consequences1. Hippocrates was also one of the first proctology surgeons, and 
his written work, “On haemorrhoids,” describes how to cut, excise and cauterize the 
haemorrhoids2. However, Hippocrates advised against surgical treatment of cancer, 
an attitude that remained predominant in medicine for about 2000 years2. 
Rectal cancer was first described in the 14th century by John of Arderne. The 
following are excerpts from his writing.  
“A bubo is a tumour developing within the anus in the rectum – with great hardness, 
but little aching. This I say, before it ulcerates, is nothing else than a hidden cancer, 
that may not in the beginning of it be known by the sight of the eye.”  
“But after passage of time it ulcerates and wastes all of the circumference of it so 
that it may never be cured with man´cure.”  
“The patient cannot keep himself from going to the privy because of the aching and 
sharp pain… hard faeces are passed and sometimes it cannot get out because of the 
stricture.”2 
Surgery for colorectal cancer was reported in a few cases in the 18th century, 
replacing medical treatment that mainly comprised enema, venae section, laxatives 
and ointments during the 19th century. Alexis Littré (Paris, France) was probably the 
first to suggest the use of a stoma for anus atresia in 1710 by creating a 
sigmoideostomy. The first stoma for a patient with rectal cancer was described in 
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1776 by the French surgeon Pillore2. At that time, surgery was seen as the last resort 
i.e. for use when all conservative treatments, including large doses of mercury, had 
failed. Pillore created a caecostomy that had a favourable immediate postoperative 
course, but the patient died from peritonitis on the 18th postoperative day. Autopsy 
showed that there was nothing wrong with the stoma, but 1 kg of mercury had lodged 
in a narrowing of the small intestine and had eroded the small intestine.2  
The first successful surgical resection of rectal cancer treatment, which was a 
transanal excision, was performed in 1826 by Lisfranc (Paris, France)1. The patient 
recovered fully with no relapse. Another 8 patients subsequently underwent the same 
operation, 6 of whom survived. This operation was performed for tumours below the 
level of the peritoneal reflection by pulling down the rectum with the tumour and 
amputating the distal rectum. According to Nettler, this was in fact an anal excision 
without any curative potential, and most patients died within two years.1 
During the second half of the 19th century, the basis of modern medicine was laid. 
This paradigm shift included a better understanding of pathology, pathophysiology 
and hygiene. The introduction of general anaesthesia enabled surgeons to develop 
more complex surgical procedures, thus setting the stage for modern surgical 
oncology. Increasing numbers of surgeons continued to carry out perineal excisions. 
Theodor Billroth is said to have excised the rectum more than 40 times before 1872. 
The course for colon cancer took a different path than that of rectal cancer, with the 
creation of an anastomosis being the most important challenge. The first successful 
resection with a primary anastomosis for large bowel cancer seems to have been 
performed by Reybard in 1833. The patient died one year later due to recurrence. The 
operation was criticized, and for a long time palliative defunctioning by colostomy 
was the suggested treatment of choice. As late as 1880, only 10 resections had been 
reported in the literature, 7 of which were failures. Later, resection and double barrel 
stoma was introduced, followed by internal anastomosis.3 
Modern treatment of rectal cancer had its start in 1906, when Miles performed a 
combined abdomino-perineal operation for rectal cancer. One stage of the operation 
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was performed via the abdomen with the creation of an end-colostomy, and the other 
via the perineum. Removal of regional lymph nodes was an important part of the 
procedure that helped reduce local recurrence rates. Miles’ major contribution was to 
identify the lymphatic spread of cancer cells upwards, downwards and laterally. He 
therefore assumed that removal of the following was essential for the cure of rectal 
cancer: the entire rectum, including the anal canal, sphincters, levator ani muscles, 
ischiorectal fat, most of the sigmoid colon and mesocolon along with the central 
lymph nodes of the superior haemorrhoidal and inferior mesenteric vessel.3 Even so, 
until 1920 there were still studies published about the natural history of untreated 
colorectal cancer. These reports showed a mean time to death of 24 months, with 
some patients surviving more than 10 years3. 
During the last century, there has been tremendous progress in terms of the 
development and improvement of surgical techniques, anaesthetic techniques, 
antibiotics, stoma care and surgical approach. In 1967, Turnbull proposed a no-touch 
technique that would avoid blood-borne metastases for colon cancer 4. The circular 
stapler for low rectal anastomosis was introduced in 1970. During the 1960s, the first 
effective chemotherapeutic agents were introduced, including fluorouracil (5-FU), 
which has remained an important part of colorectal cancer treatment for 40 years. 
During the 1980s, cure of colon and rectal cancer that was limited to a localised 
disease was considered feasible by surgical resection. However, the prognosis of 
patients with rectal cancer was dramatically inferior compared to patients with colon 
cancer due to local recurrences in more than 30% of the patients 5, 6. In 1983, the 
British surgeon Bill Heald reported a large patient series with a very low local 
recurrence rate of 4%7. He showed that a refined surgical technique that took into 
account the correct surgical planes was essential for achieving local tumour control as 
a prerequisite for cure. This technique, termed “total mesorectal excision” or TME, 
includes complete removal of the fatty tissue behind the rectal tube, its associated 
lymph nodes and the satellite tumours within its enveloping fascia, which is the 
mesorectal fascia.8 While TME was met with initial scepticism, the concept of TME 
has been adopted by the surgical community and was considered the standard surgical 
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technique for rectal cancer during the 1990s9. Currently, TME is performed not only 
in open surgery but also via laparoscopy10 and using robot-assisted techniques11.  
For colon cancer, there were basically no major changes in surgical techniques during 
this time (1980-2000). The only major treatment change was the introduction of 
adjuvant chemotherapy for lymph node positive disease. A more detailed description 
of the evolution of treatment guidelines during the last 20 years is given in Chapter 9, 
“The Evolution of Norwegian Treatment Guidelines.” 
3.2 Epidemiology 
From a global perspective, there were an estimated 12.7 million cancer cases and 7.6 
million cancer deaths worldwide in 200812. In the industrialised world, breast cancer 
in women and lung cancer in men are the most common causes of death from cancer, 
followed closely by colorectal cancer for both sexes. In Norway, around 3500 new 
cases were diagnosed in 2007. While colorectal cancer is ranked second to prostate 
cancer for men and breast cancer for women, it represents the most common cancer 
that affects both sexes.13 Approximately 5% of all men and 4% of all women in 
Norway will be diagnosed with colorectal cancer before age 75.14 
 
3.2.1 Geographical distribution 
The distribution of colorectal cancer shows great geographical variations. The highest 
incidence is in Europe and North America15, and Norway is one of the Western 
countries with the highest incidence16. In contrast, incidence rates are considerably 
lower in Africa, Asia and South America17. However, incidence rates are increasing 
even in these countries, possibly as the result of changing lifestyles that have become 
more westernized. There is less variation in terms of incidence within countries 
compared to variations between countries, although some studies have shown higher 
incidence in subpopulations of patients with low income and low educational levels18. 
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3.2.2 Incidence according to age and sex  
While the incidence of colon cancer is evenly distributed in both sexes, there are 
considerable differences in distribution according to sex for rectal cancer. For 
unknown reasons, rectal cancer occurs about 50% more often in men than in women. 
With median ages of 75 years for colon cancer and 72 years for rectal cancer, in 
Norway colorectal cancer is mostly a disease that affects elderly patients. The 
incidence increases with increasing age. Patients under 40 years of age are 
uncommon, with this age group accounting for approximately 2–4% of patients with 
colorectal cancer.  
  
 
 
 
 
 
 
 
 
 
Figure 1. Trends in age- and sex-adjusted incidence rates. Five-year relative survival 
and mortality rates for a) colon cancer and b) rectal cancer. Relative survival up to 
15 years after diagnosis for c) colon cancer and d) rectal cancer in men and women. 
Source: Cancer in Norway 2008 
a) Colon Cancer b) Rectal Cancer 
c) Colon Cancer d) Rectal Cancer 
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Figure 2. Relative survival according to sex for a) colon cancer and b) rectal cancer 
and according to stage for c) colon cancer and d) rectal cancer.  
Source: Cancer in Norway 2008 
 
 
3.2.3 Anatomical distribution of colon and rectal cancer 
The colon and rectum are located in the abdominal cavity (Figure 3), starting in the 
right lower quadrant with the caecum and its accompanying appendix vermiformis 
a) Colon Cancer b) Rectal Cancer 
c) Colon Cancer d) Rectal Cancer 
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where the small bowel enters the large bowel at the valvula Bauhini. The colon then 
continues upward into the ascending colon before it turns via the right flexure to the 
transverse colon. This part of the colon, and continuing until the last third of the 
transverse colon, receives its blood supply from the superior mesenteric artery and is 
usually defined as the “right colon”. The remaining part of the colon consists of the 
left flexure and extends downward into the descending colon before it reaches the 
sigmoid colon. This part, usually termed the “left colon,” is supplied with blood by 
the inferior mesenteric artery. The promontory usually indicates the recto-sigmoidal 
junction, and the rectum is usually defined as the section that is 15 cm from the anal 
verge. The major blood supply of the rectum is the superior rectal artery, a branch of 
the inferior mesenteric artery, along with the often-inconsistent middle rectal artery 
that emerges from the internal iliac artery and collateral vessels from the inferior 
rectal artery. 
 
Figure. 3: Gross anatomy of the colon. 
Approximately one-third of all colorectal cancer patients have rectal cancer, while 
two-thirds have colon cancer. With regard to colon cancer, 50% of the tumours are 
localized in the sigmoid colon, 25% in the right colon and 25% in the remaining parts 
of the large bowel i.e. the right flexure, transverse colon, left flexure or descending 
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colon. However, recently a trend of increased incidence of right-sided tumours has 
been shown that is particularly evident in the oldest patients.19 With regard to rectal 
cancer, there is an even distribution of tumours located in the upper, middle and 
lower third of the rectum. 
 
3.3 Etiology 
Although there are defined genetic syndromes associated with colorectal cancer, 
environmental factors undoubtedly also play a major role. Specifically, immigrants 
moving from an area of low incidence to an area of high incidence are at greater risk 
of developing the disease. This has been shown for Japanese moving to Hawaii and 
California, for Puerto Ricans moving to the USA, and for European-born Jews who 
moved to Israel who were compared to Africa-born Jews.3 
A number of dietary factors are proposed to be important in the development of 
colorectal cancer, including a lack of dietary fibre, a diet high in animal fat and low 
vegetable intake20. Excessive alcohol consumption, low potassium intake, low 
selenium intake, too much fluoride and/or low folate have also been suggested as 
contributing factors, but the evidence is not clear20. 
Long-standing inflammation, as in ulcerative colitis, is a well established risk factor 
for colorectal cancer21, as are genetic predisposition22 and smoking23.  
 
3.4 Genetic factors 
The cause of colorectal cancer can be genetic or the consequence of long-standing 
inflammatory or sporadic. Approximately 75% of adenocarcinomas occur 
sporadically, and 25% of the patients are thought to develop colorectal cancer 
secondary to familial syndromes22. However, only 5% of cases can be identified as 
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the result of a defined genetic condition. The best-known syndrome is hereditary non-
polyposis colon cancer or HNPCC, which involves a defect in one of the mismatch 
repair genes (MMR). Other genetic syndromes include familial adenomatous 
polyposis syndrome (FAP), in which there is a mutation in the tumour suppressor 
gene APC (adenomatous polyposis coli), Peutz-Jeghers syndrome and juvenile 
polyposis syndrome22. 
Traditionally, the dominant theory of colorectal cancer development has been the 
adenoma-carcinoma sequence, which posits that carcinomas of the colon evolve from 
pre-existing, pre-malignant lesions, such as adenomas24. However, only a few 
adenomas transform into cancer24. On the other hand, malignant tumours of the 
colorectum derived from flat or depressed de novo lesions of the mucosa are 
described in up to 30% of cases without preceding polypous lesions25 
There are two histological types of polyps, adenoma polyps and hyperplastic polyps. 
Hyperplastic polyps are probably not associated with an increased risk of cancer. The 
transformation of polyps from adenoma to carcinoma involves several genetic 
alterations:  
a. Chromosomal instability  
b. Epigenetic changes  
c. Microsatellite instability 
Chromosomal instability represents changes at the chromosomal level, with 
alterations in the number of chromosomes or parts of the chromosomes in all somatic 
cells. Mutation of the APC gene is one cause of this type of alteration22, 26. 
Epigenetic changes involve changes in DNA methylation that do not alter the genome 
but which do alter the expression of certain genes and which can turn off gene 
expression. 
Microsatellites are repetitive sequences of DNA. The length of these microsatellites 
varies greatly from person to person, but each person has microsatellite sequences of 
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a set length. These repeated sequences are common and normal. If the DNA repair 
genes are defective (e.g. mismatch repair genes), these sequences are more prone to 
have changes that result in alterations in genes and thus in altered protein expression. 
Clinically, microsatellite instability can be detected in 15–20% of sporadic colorectal 
cancers. These cancers are associated with particular clinical and morphological 
findings;27-30 specifically, they are more often found in the right colon and are often 
larger tumours that show low differentiation and that have a low incidence of 
metastases. Chromosomal instability is found in 80–85% of patients with colon 
cancer, and are more often in the left side of the colon and show a higher frequency 
of metastatic spread. 
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4. Clinical presentation and diagnosis  
Early stage colorectal cancer is asymptomatic. Clinical symptoms are scarce and 
develop slowly over time. There are, however, a few symptoms or signs that most 
often lead to diagnostic evaluation. These include lower gastrointestinal bleeding or 
occult bleeding with resultant microcytic/iron deficiency anaemia, changes in bowel 
habits and abdominal pain.31 Colorectal cancer can also progress and present as large 
bowel obstruction or even as perforation, either at the site of the tumour or 
proximally, usually in the caecum due to ischemia of the bowel wall as the result of 
dilatation of the proximal colon and increased tension in the bowel wall. Up to 20–
25% of colon cancer cases present as emergencies; in contrast, only a small number 
of rectal cancer cases present as emergencies32, 33.  
Locally advanced tumours may present with other symptoms, such as with 
pneumaturia if a colovesical fistula is present, with hydronephrosis if the growth 
obstructs the ureter or with other symptoms, depending on the tumour location. 
4.1 Diagnosis  
There are several aspects of the colorectal cancer patient evaluation. First, a diagnosis 
must be established; second, the extent of the disease must be established; and third, 
the patient’s fitness for treatment must be determined. 
The diagnosis is usually made in the elective setting via endoscopy, i.e. colonoscopy 
and/or proctoscopy. The barium enema technique used in the past has been mostly 
abandoned, and virtual colonoscopy, or CT colonography, is currently considered just 
as good as colonoscopy for detecting cancers34. Several studies have shown a 
detection rate of >95% for polyps ≥10 mm and close to 100% sensitivity for cancer35; 
thus, this modality has gained popularity in recent years. However, colonoscopy is 
still the gold standard, as it is known to have high sensitivity and specificity. The 
effectiveness and sensitivity depend, however, on the skill and experience of the 
endoscopist, both in terms of reaching the caecum and detecting the relevant 
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pathology36. For rectal cancer, in addition to colonoscopy, clinical examination 
(digital palpation and rigid proctoscopy) is of the greatest importance for correctly 
interpreting modern imaging results. This is the key for describing the clinical 
appearance of the tumour, such as the correct distance from the anal verge and upper 
level of the pelvic floor to the inferior border of the tumour, and for noting signs of 
tethering or infiltration into neighbouring structures. Correct interpretation of imaging 
results is critical for making the best treatment decisions regarding choice of surgical 
procedures or use of neoadjuvant preoperative treatment.  
 
4.2 Preoperative workup 
For assessing the distant spread of colorectal cancer, traditional imaging consisted of 
plain ultrasound of the liver and a chest x-ray examination. However, CT scan of the 
chest has a higher sensitivity (75–87%)36 and is usually the method of choice 
nowadays. For the liver, both contrast-enhanced CT examination and contrast-
enhanced ultrasound have higher sensitivity and specificity and are the preferred 
methods36. Accordingly, it is currently recommended in many countries that CT scan 
of the abdomen and chest should be performed as part of the routine work-up, with 
supplementation of other examinations if relevant, such as MRI of the liver, contrast-
enhanced ultrasound of the liver, gynaecological examination, cystoscopy or other 
urologic examinations (cystography, urography). PET (positron emission 
tomography) combined with CT is a new modality that focuses on metastatic lesions 
that are hard to detect by imaging, but PET has not yet become a routine part of the 
preoperative workup37. 
At present, serum-carcinoembryonic antigen measurement (CEA) is the only 
biochemical tumour marker that is used widely for colorectal cancer. Although, CEA 
is limited as a diagnostic aid as about one-third of patients have normal levels, its role 
in follow-up is better defined27,38. However, highly elevated preoperative CEA levels 
indicate disseminated disease. 
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Preoperative workup for rectal cancer 
 For rectal cancer, there is convincing evidence that some tumours should be treated 
with preoperative radiochemotherapy when the local tumour staging indicates locally 
advanced disease. In contrast, preoperative neoadjuvant treatment is virtually never 
indicated in colon cancer for localised tumours without metastases. The decision to 
give preoperative radiochemotherapy for rectal cancer is based on a MRI scan or/and 
endorectal ultrasound. Both modalities have advantages and disadvantages in terms 
of overstaging and understaging errors for T- and N-status. 
MRI is usually the method of choice for staging, and T3 and T4 staging by MRI is 
correct in approximately 85% of tumours39, 40. Even more importantly, MRI can 
predict involvement of the circumferential resection margin by the tumour with a 
sensitivity of 94% and a specificity of 85%41. The MERCURY trial showed that MRI 
could predict the circumferential resection margin within 0.5 mm of the margin found 
by histopathology examination42. Nodal staging is less accurate, with 85% of 
predicted lymph nodes on MRI confirmed by histopathological examination; in 
addition, a negative MRI cannot predict negative nodes.40 
Endorectal ultrasound (ERUS)  
One study showed that ERUS is accurate for early stages of tumours (i.e., 
intramucosal neoplasia, T1 and T2), with a sensitivity of 94% and a specificity of 
86%; however, its accuracy is lower in more advanced cancers43. There are still 
limitations regarding N-stage, and the mesorectum and peritoneum cannot be 
visualised. This is a serious limitation in terms of predicting involvement of the 
circumferential resection margin. Thus, the role of ERUS in more advanced tumours 
is limited compared to MRI40. 
In 1990, randomised trials compared preoperative radiotherapy with postoperative 
therapy and also compared preoperative therapy of different doses to surgery alone, 
along with the addition of chemotherapy44. Preoperative radiotherapy showed lower 
local recurrence rates, but there was no effect on survival compared to postoperative 
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radiotherapy45. It was also demonstrated that postoperative radiotherapy had greater 
toxicity and was associated with lower compliance46. 
Two important randomized studies compared preoperative radiotherapy with surgery 
alone.47, 48. Both studies found that preoperative radiotherapy reduced the risk of local 
recurrence by approximately 50%. The Swedish trial, but not the Dutch TME trial, 
showed an influence on survival. The Swedish trial was performed before TME 
surgery was established. Results from these trials resulted in guidelines in Sweden 
and the Netherlands that are more liberal in terms of the use of preoperative 
radiotherapy compared to Norway—in Norway, preoperative radiochemotherapy is 
restricted by criteria indicating circumferential resection margin (CRM) involvement. 
This is based partly on one of the studies from the Norwegian Rectal Cancer Registry 
showing that a predicted CRM of ≤3 mm is a risk factor for local failure49. 
Accordingly, the Norwegian guidelines as of 2010 state that patients with T4 tumours 
or with tumours that have a predicted CRM of ≤3 mm from either the tumour or a 
malignant deposit, i.e. a lymph node or satellite tumour, should be offered 
preoperative radiochemotherapy. Further, if a non-radiated tumour turns out to have 
involved CRM, postoperative radiochemotherapy is recommended. 
 
4.3 Fitness for treatment 
Treatment of colorectal cancer is associated with an overall morbidity of 15–20%50 
and a perioperative mortality of 3–5% 51. Due to the characteristics of the disease, 
half of the patients are elderly and have increased comorbidities; thus, assessment of 
fitness for treatment is particularly important to achieve the best possible treatment 
outcome52, 53. While curing the cancer is the major treatment goal for the majority of 
patients, elderly and frail patients may be better served by an approach tailored to 
their physical and mental condition in terms of developing an individual treatment 
goal. It has been shown that even octo- and nonagenarians tolerate surgery for 
colorectal cancer quite well provided that risk factors are identified and primary 
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surgery is optimised to minimize complications54. This involves a general medical 
examination with a special focus on respiratory and cardiovascular status. In 
particular, the following may need attention or treatment in order to minimize 
perioperative risk factors: poor nutritional status, poorly controlled diabetes mellitus, 
frailty, jaundice, previous surgery, previous pulmonary embolus or deep vein 
thrombosis, dementia, reduced kidney function and other conditions. Anaemia may 
need to be treated. Finally, the function of the sphincter apparatus needs to be 
assessed to make an informed decision of whether to use a stoma. 
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5. Staging 
Staging, i.e. systematic examination of the patient to determine the extent of the 
malignant disease, is very important for determining the patient’s prognosis. Staging 
is even more important for making the best treatment decisions for the individual 
patient. The first classification system that had clinical importance was proposed by 
Dukes in 1930. This system was based on the pathologist’s detailed description of the 
removed specimen with regard to tumour invasion into or beyond the bowel wall and 
assessment of whether regional lymph nodes were affected by metastatic tumour 
cells55: 
Stage A: Growth of the primary tumour limited to the wall of the rectum or colon, 
without extension into the perirectal or pericolic tissue 
Stage B: The growth of the primary tumour extends through the bowel wall into the 
perirectal or pericolic tissue 
Stage C: Any level of growth of the primary tumour combined with the presence of 
metastases to the regional lymph nodes are involved with the tumour 
Stage D: Presence of disseminated disease regardless of any level of tumour growth 
or lymph node metastases 
The clinical importance of Dukes’ classification system stems from its foundation on 
lymph node status, which has strong prognostic power; in fact, the presence of lymph 
node metastases is currently considered the single most important factor for 
predicting treatment outcomes and is the main criterion for determining the use of 
adjuvant chemotherapy. 
In the years that followed, it became clear that additional factors influenced prognosis 
and that there was need for a more detailed classification system, and the “tumour-
node-metastasis” or TNM staging system was introduced in 1978. The latest (AJCC 
7th edition) version of the TNM staging system is shown below.  
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5.1 T categories for colorectal cancer56 
Tx: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: Carcinoma in situ; intraepithelial or invasion of lamina propria 
T1: Tumour invades submucosa 
T2: Tumour invades muscularis propria 
T3: Tumour invades through the muscularis propria into pericolorectal tissues 
T4a: Tumour penetrates to the surface of the visceral peritoneum 
T4b: Tumour directly invades or is adherent to other organs or structures 
5.2 N categories for colorectal cancer56 
Nx: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis in 1–3 regional lymph nodes 
N1a: Metastasis in one regional lymph node 
N1b: Metastasis in 2–3 regional lymph nodes 
N1c: Tumour deposit(s) in the subserosa, mesentery, or nonperitonealized periocolic 
or perirectal tissues without regional nodal metastasis 
N2: Metastasis in 4 or more regional lymph nodes 
N2a: Metastasis in 4–6 regional lymph nodes 
N2b: Metastasis in 7 or more regional lymph nodes 
 
5.3 M categories for colorectal cancer56 
M0: No distant metastasis 
M1: Distant metastasis 
M1a: Metastasis confined to one organ or site 
M1b: Metastasis in more than one organ/site or the peritoneum 
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The Cancer Registry of Norway, established in 1951, has traditionally used the terms 
“localised” or “regional” in its main database to indicate lymph node metastases.57 
However, the Norwegian Rectal Cancer Registry, and (after 2007) the Norwegian 
Colorectal Cancer Registry, uses the TNM classification system. For this reason, the 
two first papers in this thesis, which are based in part on data from the main database 
of the CRN, were limited in terms of being able to distinguish more than only 
between lymph node positive and lymph node negative disease. The TNM 
classification (AJCC 6th edition) was used in paper III. 
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6. Treatment of colorectal cancer 
6.1 Treatment options 
The principles of surgery for colorectal cancer are the same as for open or 
laparoscopic surgery, but the surgery can be performed with either curative or 
palliative intention. For the universal goal of curative resection, it is important to 
remove the tumour with a sufficient margin proximal or distal to the tumour and to 
ensure sufficient removal of the mesocolon or mesorectum with its vascular pedicle 
and its accompanying lymph nodes. For palliative procedures, the clinician must 
make the best choices according to the individual treatment goals to preserve the best 
possible quality of life. These choices can include limited resection, a bypass, a stoma 
or endoscopic procedure, stenting of an obstructed colon or argon laser treatment of a 
bleeding tumour. 
6.1.1 Curative or palliative resection 
About 25–30% of colorectal cancer patients present with disseminated disease at the 
time of diagnosis, and about 30–40% of patients who are operated with curative 
intent will be diagnosed with recurrence during follow-up. The last years, the 
distinction between curative and palliative resection has become blurred. Most people 
agree that the presence of widespread carcinomatosis is an indication for palliative 
procedures, or even for options other than surgery. Widespread lymph node 
metastasis, i.e. metastasis outside the normal resection margins, widespread lung 
metastases and/or disseminated liver metastases indicate palliative treatment. On the 
other hand, resectable pulmonary or liver metastases, and even limited 
carcinomatosis, are now treated in a multimodal fashion that includes surgery and 
chemotherapy. The use of intraperitoneal chemotherapy combined with hyperthermia 
(HIPEC) shows a 5-year survival of 20–50%58. Careful evaluation of all patients by a 
multidisciplinary team (MDT) is now considered the standard of care. It is important 
that the MDT includes competence with curative and palliative treatment. 
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6.2 Colon cancer 
The mainstay in the treatment of colon cancer with intention to cure is removal of the 
tumour with its accompanying draining lymph nodes. To achieve curative surgery, a 
sufficient margin (5–10 cm) on both sides of the tumour is removed, and an adequate 
length of the supplying vessels with the draining lymph nodes is removed en bloc as 
well. The extent of blood vessel ligation is still debated (i.e., D2 or D3 resection, 
Figure 4). If the tumour is invading another organ, it is crucial to remove the other 
organ en bloc whenever possible. These principles apply regardless of whether open 
or laparoscopic resection is performed. As an exception to these general rules, 
removal of a small possibly polypous tumour by endoscopic resection can be 
sufficient treatment when the tumour is either Tis or T1 with a sufficient free margin 
and without invasion into deeper layers of the submucosa.59 
Following excision, bowel continuity is restored if the patient’s general health is 
adequate. The patient’s general health must be taken into consideration when 
deciding upon use of a stoma because of the risk of complications. Anastomotic 
leakage is associated with mortality of up to 39%60, and data also suggest that in 
addition to the risk of postoperative mortality, there is also decreased long-term 
survival61. The risk factors that are typically reported include multivisceral resections, 
low anterior resections and general fitness of the patient, as well as preoperative 
nutrition status, blood supply, anastomotic tension and operation in an emergency 
setting62. 
The extent of colon resection is determined by the level of ligation of the blood 
supply, and, accordingly, the number of lymph nodes that are removed. The more 
central and radical the surgery, the greater the loss of blood supply to the remaining 
colon and the longer the segment of colon that has to be removed. There are 
diverging opinions on how radical surgery should be, and this remains an on-going 
debate63,64. 
If there are signs of adherence or infiltration into other organs, such as the small 
bowel, abdominal wall, uterus or bladder, but no other signs of advanced disease or 
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distant metastases, efforts should be made to remove the tumour en bloc to achieve an 
RO resection (i.e. macroscopically- and microscopically-free margins); still, complete 
removal of all cancer tissue is an unconditional prerequisite for a favourable 
prognosis65. 
 
Figure 4. Colon resection: a) D1 resection with removal of only th elymph nodes 
near the tumour; b) D3 resection with removal of the central lymph nodes as well. 
Source: Norwegian Directorate of Health, Nasjonalt handlingsprogram for 
diagnostikk og behandling av kreft i tykk- og endetarm 
 
What is less controversial is the importance of operating in the correct embryological 
planes in complete mesocolic excision or CME surgery. In the early 1980s, Heald 
showed that for rectal cancer, removing the mesorectum with its intact fascia resulted 
in a better prognosis than if the fascia was not removed.8 Recent results suggest that 
the same holds true for colon cancer66. The type of resection depends on the location 
of the tumour. Figure 5 shows the most common types of resection according to 
tumour location. 
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In 2007, Hohenberger et al.64 published a study showing a remarkable increase in 
survival of colon cancer patients in recent decades at his institution, with overall 5-
year survival of 90% in the most recent period for patients with stage I, II and III 
colon cancer. He introduced the concept of CME for colon cancer based on the same 
principles that support TME for rectal cancer. In addition, he advocated for central 
dissection with removal of the lymph nodes closest to the superior mesenteric artery 
on the right side and removal of the inferior mesenteric artery on the left side. For 
cancers in the transverse colon, he also recommended removing the lymph nodes 
along the greater curvature of the stomach. Hohenberger et al. showed that patients 
who had more than 28 lymph nodes  removed had a better prognosis than patients 
with fewer than 28 lymph nodes removed. 
In a study conducted in Leeds, England, West et al.67 looked at the quality of the 
removed specimens and found that intact mesentery of the colon was related to better 
survival compared to non-intact mesentery. He went on to compare the English 
specimens with specimens from Erlangen, Germany (from the institution with which 
Hohenberger is affiliated) and from a Japanese institution. West et al. found that 
almost all specimens from Erlangen had an intact mesentery, in contrast with 
approximately 50% of those in Leeds and 70% in the Japanese medical centre66, 68. 
Several studies show better survival for patients in whom more lymph nodes are 
removed and identified69, 70. Some claim that this is due to better staging and to 
additional use of chemotherapy, while others claim that a more central dissection 
with removal of malignant lymph nodes in itself can influence prognosis64. Still 
others claim that tumours with many enlarged lymph nodes may have different 
biological properties or that the patient may have a more activated immune system 
and therefore a better prognosis. Tumours with microsatellite instability tend to have 
more lymph nodes identified28. 
An American study showed that there was a trend of increased lymph node harvest 
over time but that this did not influence the proportion of patients with lymph node 
positive disease71. Survival increased even though the number of stage III patients did 
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not, calling into questioning the role of stage migration as the reason for survival 
gain. 
One randomized trial and several additional trials compared D2 resection and D3 
resection for sigmoid cancers.72 A slight survival gain was seen with central ligation. 
On the other hand, studies investigating the location of the malignant lymph nodes 
found that in approximately 5% of sigmoid cancers, the only malignant lymph nodes 
with metastases were seen apically in the D3 area, i.e. so-called “skipped 
metastases”73. Finally, with regard to lymph node harvest in rectal cancer, a 
multivariate analysis showed that preoperative chemoradiotherapy reduces the lymph 
node harvest, probably by reducing the size of the nodes and thus making it harder to 
find and remove them74. 
There are several treatment options for obstructing left-sided colon cancer. Recently, 
use of a self-expanding metallic stent (SEMS) has become an option that is termed “a 
bridge to surgery.” The reason for this term is that substantial morbidity and mortality 
is associated with acute surgery for left-sided bowel obstruction75. Therefore, by 
using SEMS, the tumour can be reopened with a stent; subsequently, the obstructed 
bowel can deflate, the patient can recover and definite surgery can be performed in an 
elective setting with reduced mortality. There has been some criticism regarding the 
possibility of perforation of the tumour, tumour spillage and reduced long-term 
survival76. No clinical trial has been performed that randomises patients between 
SEMS and subtotal colectomy. One study was ended early due to serious 
complications77.  
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Figure 5. The most common surgical resections of the colon: a) right hemicolectomy; 
b) extended right hemicolectomy; c) subtotal colectomy; d) left colectomy; e) 
resection of the sigmoid colon. Source: Norwegian Directorate of Health, Nasjonalt 
handlingsprogram for diagnostikk og behandling av kreft i tykk- og endetarm 
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6.3 Rectal cancer 
In addition to the principle of removal of the tumour with its accompanying lymph 
nodes, there are some key differences between rectal and colon cancer. First, the 
distance to the anal sphincter plays a major role for the choice of procedure. Second, 
the rectal tube is, at least for the lowest part, enveloped by vital structures of the 
pelvis and has to be dissected free using great care. Heald showed that the most 
important step in avoiding local recurrence is complete removal of the rectum, 
including the perirectal fat (which is enveloped by the mesorectal fascia) using 
meticulous dissection techniques. This technique, termed total mesorectal excision 
(TME), has become the standard of care during the past two decades. Third, there is 
strong evidence that some tumours of the rectum should be treated with neoadjuvant 
chemotherapy before surgery78, 79. This is indicated when preoperative evaluation (i.e. 
clinical examination and imaging) shows that the circumferential resection margin or 
CRM may be threatened. According to current Norwegian guidelines, T4 tumours or 
tumours with predicted CRM ≤3 mm should be irradiated preoperatively80. 
It is generally accepted that tumours in the upper part of the rectum (10–15 cm from 
the anal verge) should be dealt with using anterior resection, including removal of the 
distal part of the sigmoid colon and removal down to at least 5 cm distal of the 
tumour. This is termed partial mesorectal excision or PME80. There is still a debate as 
to whether the vascular supply should be divided close to the departure from the aorta 
(central ligation of the inferior mesenteric artery) or after the departure of the left 
colic artery (superior rectal artery)63. Usually the colon is anastomosed to the 
remaining rectum with a stapler. 
There are some specific things to be aware of when treating tumours in the middle 
and lower rectum. Whenever the tumour involves the sphincter apparatus, the 
decision to perform an abdominoperineal excision is not controversial. When the 
tumour is located in the lower rectum and above the pelvic floor, a low anterior 
resection is often feasible. A distal margin of at least 1 cm is considered adequate if 
the tumour is radiated preoperatively81. However, an anastomosis close to the pelvic 
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floor may be associated with inferior functional results in terms of reduced 
continence, urge or emptying disorders82. Accordingly, these aspects must be 
discussed carefully with the patients before making a final decision about the surgical 
procedure. In cases involving a low anterior resection, a defunctioning stoma is 
recommended, which can be reverted after 6–12 weeks if the anastomosis appears to 
be healed. 
Abdominoperineal excision has traditionally been performed with the patient in the 
lithotomy position. This position allows good access to the abdomen and pelvic 
cavity. However, the perineal part of the procedure may be influenced by limited 
access to the perineum and poorer visibility of the surgical field. Data from the 
Norwegian Rectal Cancer Registry showed that abdominoperineal excision was 
associated with 4 times as many perforations and 2–3 times more R1 resections 
(involved margins) than was low anterior resection83. Further, conventional perineal 
dissection has been criticised as resulting in coning of the specimen at the level of the 
pelvic floor, leading to insufficient CRM. Recently, a new approach termed extended 
abdominoperineal excision was presented by Holm and coworkers84. This technique 
includes removal of the levator muscles together with the rectum. It avoids dissection 
into the plane between the distal rectum and the pelvic floor by using limited 
dissection from above to a level that is designated by the lower coccygeal joint and 
the seminal vesicles in males. Perineal dissection is performed with the patient in a 
prone jackknife position after completion of the transabdominal part of the procedure. 
This technique, which is increasingly being adopted by Norwegian surgeons, seems 
promising, although few long-term oncologic results are available85.  
6.4 Palliative interventions 
While most surgical procedures for colorectal cancer are performed for the purpose of 
cure, some patients are treated with the intention to restore or maintain quality of life. 
Palliative intervention is beyond the scope of the thesis. Briefly, colorectal resection 
may be warranted when bleeding, perforation or bowel obstruction is present. Internal 
bypass or creation of a stoma should be considered. Over the last decade, colorectal 
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stenting has become an excellent alternative for many patients with incurable 
disease86. Another important scenario is the presence of an asymptomatic tumour 
with disseminated disease. There are several randomized trails at present that are 
testing whether patients with an asymptomatic primary tumour with disseminated 
disease benefit from a resection. Some earlier studies showed better survival for 
patients who had the tumour removed, but these studies were not randomised and 
they may have had selection bias87. However, the success of any palliative 
intervention depends strongly on an individualized approach that takes into account 
the wishes of the patient, the patient’s functional status and where the patient is in 
terms of the course of the disease. 
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7. Histopathological evaluation 
Histopathological examination of the surgical specimen is of crucial importance. The 
pathology report is the basis for confirming complete removal of the tumour (i.e. R0 
resection), determining patient prognosis (i.e. TNM stadium) and guiding further 
treatment, e.g. adjuvant chemotherapy for patients with lymph node metastases. 
Careful pathological evaluation and reporting is just as important as careful surgery.  
The pathology report should contain certain information, such as tumour localisation, 
diameter, histologic type, histologic grade, infiltration, shortest distance from tumour 
to resection margin, distance from tumour to the end of the resection margin, number 
of lymph nodes identified, number of lymph nodes with metastases, extramural 
venous or perineural infiltration, TNM classification, UICC stage and any other 
important pathological findings. Further, the quality of the surgical specimen, e.g. 
preservation of intact mesorectal fascia, should be reported as well. 
In Norway, efforts have been made to standardise the pathology report. For this 
purpose, a national report template has been developed and its use is recommended 
for all pathology departments88, 89. However, so far fewer than half of the pathology 
departments use the national template88.  
Additional information that should be included in the pathology report is still being 
discussed and might include localisation of positive lymph nodes, quality of the 
mesocolon, length of the removed apical vessel, area of the removed mesocolon66 and 
perhaps even some genetic markers, such as MSI.29  
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8. Norwegian Colorectal Cancer Registry 
Until the early 1990s, most clinicians held the traditional view that patients should be 
admitted to surgery after the diagnosis of cancer of the colon or rectum without 
further investigation; poor treatment outcomes were seen as a natural part of the 
disease. This was particularly true for rectal cancer, and local recurrence rates were 
reported as being 30% or even higher90. However, the British surgeon Bill Heald 
showed that local recurrences were mostly related to inferior surgical technique that 
was performed using stump manual dissection of the pelvic structures. This leads to 
incomplete removal of the perirectal fat (i.e. the mesorectum), leaving either 
metastatic lymph nodes or tumour satellites in the pelvis as the cause of recurrence. 
Furthermore, inferior surgical techniques were associated with either perforation of 
the rectum, causing spillage of tumour cells, or bleeding from the presacral venous 
plexus and a high frequency of pelvic nerve damage. Heald showed that local 
recurrences could be avoided by meticulous sharp dissection along the mesorectal 
fascia, thus removing the entire mesorectal fat. This is termed total mesorectal 
excision (TME).  
In the early 1990s, the concept of TME was accepted as the national standard of 
surgery for rectal cancer. Late in 1993, the Norwegian Rectal Cancer Registry 
(NRCR) was established. At this time, it became standard for all rectal cancer 
patients undergoing surgery to be registered prospectively, and each institution 
received feedback about their own results, including local recurrence and survival. 
The goal was to reduce local recurrence to approximately 10% by implementing 
TME surgery. This was paralleled by the introduction of TME surgery via surgical 
workshops led by Bill Heald. As a consequence, several low volume hospitals 
stopped treating rectal cancer, and rectal surgery was limited to surgeons trained in 
the Norwegian subspecialty of gastrointestinal surgery. Several publications have 
emerged from analysis of data from this registry that document the effects of these 
measures91-93. Starting in 2007, the NRCR was expanded to include colon cancer and 
became the Norwegian Colorectal Cancer Registry (NCCR). In contrast to the main 
database of the CRN, this registry includes a large number of clinical-pathological 
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variables and thus constitutes a national quality registry. The NCCR is considered to 
be the first quality registry of the CRN. As such, it serves as a prototype for emerging 
registries for other malignant diseases, such as breast cancer, prostate cancer and 
others. 
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9. Evolution of Norwegian Treatment Guidelines 
The Norwegian Colorectal Cancer Group (NGICG) consists of surgeons and 
oncologists who are centrally involved in colorectal cancer and other relevant 
specialties. The NGICG initiated and promoted the NRCR and the development of 
Norwegian guidelines for diagnosis and treatment of colorectal cancer. Due to overall 
dismal outcomes, the main focus was on local control of rectal cancer as the 
predominant problem. The Norwegian policy focused on surgery as the most 
important key to improvement, while preoperative radiotherapy was used 
occasionally and purely at the discretion of the individual surgeon. From 1994 to 
1996, TME was recommended and then considered mandatory for all hospitals that 
treated rectal cancer. From 2000, the guidelines recommended preoperative 
radiotherapy for T4 tumours or clinically fixed tumours. In 2003, the guidelines were 
modified to recommend obligatory preoperative imaging with MRI, preoperative 
radiotherapy for patients with predicted CRM ≤3 mm and the compulsory use of a 
multidisciplinary team.  
With regard to colon cancer, the treatment strategy was unchanged during the same 
time except for the recommendation of adjuvant chemotherapy for patients with pN+ 
disease up to 75 years of age. This recommendation was implemented in 1997–1998.  
In 2010, the Norwegian guidelines for the diagnosis and treatment of cancer of the 
colon and rectum were reformulated by the NGICG based on the best available 
evidence. The reformulation was endorsed by the National Health Directorate. The 
guidelines are publicly accessible as a comprehensive edition and are generally re-
evaluated every other year. However, the NGICG is responsible for deciding when 
changes must be considered due to new evidence. 
The NRCR may be considered vital in terms of setting the current national standard 
of care for colorectal cancer, and it has been the source of numerous research projects 
that serve as the basis for continuous scientific evaluation, reports and other efforts to 
further improve treatment outcomes of colorectal cancer in Norway. 
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Figure 6. Evolution of colorectal treatment guidelines in Norway.  
Courtesy British Journal of Surgery 
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10. Aim of the study 
The aim of this study was to analyse the impact of the implementation of national 
guidelines for the treatment of patients with colon and rectal cancer on outcomes at a 
national level. While treatment guidelines focused strongly on rectal cancer in terms 
of optimal local tumour control, adjuvant chemotherapy was introduced for the 
subgroup of patients with regional lymph node metastases, i.e. pN+ disease, who are 
≤75 years old. 
The objectives of the study were as follows: 
1. Paper I: To compare survival of patients curatively treated for cancer of the 
colon and rectum before and after implementation of national treatment 
guidelines
2. Paper II: To study possible differences in survival between patients treated for 
colon or rectal cancer by analysing excess mortality, i.e. mortality related to 
colon and rectal cancer, during the 5-year period after diagnosis 
3. Paper III: To investigate lymph node harvest in curative resection for colon 
cancer in a national cohort and to identify factors related to poor lymph node 
harvest and their influence on diagnosing lymph node positive disease  
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11. Patients and methods 
11.1 Databases 
We used data from the Cancer Registry of Norway (CRN) to analyse data from a 
national perspective.  
Data from 1994–2003 in the main CRN database were used to analyse the survival of 
patients curatively resected for cancer of the colon or rectum before and after the 
introduction of national guidelines (objectives 1 and 2 in the previous section). Data 
from the quality registry of colorectal cancer, i.e. the Norwegian Colorectal Cancer 
Registry, for the years 2007 and 2008 were used to study factors related to 
differences in lymph node harvest in curative resection for colon cancer. Reporting of 
all patients with a diagnosis of cancer to the CRN and NCCR is mandatory by law in 
Norway, which ensures high completeness and quality of data. 
11.2 Patients 
We identified all patients diagnosed with cancer of the colon and rectum from 
January 1, 1994 to December 31, 2003 in the main CRN database. We combined 
these data with data from the Norwegian Rectal Cancer Registry to obtain more 
detailed clinical information in order to differentiate between colon and rectal cancer. 
Tumours located up to 15 cm from the anal verge were defined as rectal cancer. All 
other tumours (>15 cm above the anal verge) were defined as colon cancer. Cancers 
of the colon or rectum were defined as histologically proven adenocarcinoma, and all 
other tumours were excluded from the analysis.  
To analyse patients treated with curative intent, patients undergoing major resections 
were included while patients were excluded who were treated with minor procedures, 
such as local resections, polypectomies or non-resective procedures such as diverting 
stoma. Further, we excluded patients with more than one cancer at different sites, i.e. 
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synchronous cancers, or who had cancers at different times, i.e. metachronous 
cancers, as well as patients with distant metastases at the time of surgery.  
Mortality data were provided by the Norwegian Cause of Death Registry. To study a 
5-year follow-up period, dates of death were provided up to December 31, 2008. 
Complete follow-up was ensured by use of the unique 11-digit personal number 
provided to every citizen of Norway. Patients who were alive on December 31, 2008 
were censored, and patients who had emigrated during the 5-year period were 
excluded. 
Regarding objective 3, detailed clinical and pathological data for all patients with 
colon or rectal cancer were available starting on January 1st from the Norwegian 
Colorectal Cancer Registry. We identified all patients with adenocarcinoma of the 
colon who were diagnosed in 2007 and 2008 and who underwent major curative 
resection using the same criteria for inclusion as applied for objectives 1 and 2., i.e. 
exclusion of patients treated with minor or non-resective procedures, distant 
metastases, those with pathological data missing, and those with either synchronous 
or metachronous tumours.  
11.3 Time periods and time intervals 
We compared data from 1994–1996 with data from 2001–2003. The Norwegian 
Rectal Cancer Registry was established in late 1993; therefore reliable information 
that could differentiate between rectal and colon cancer was available in 1994. We 
wanted to compare the early period after introduction of national guidelines with a 
later period when the guidelines had been implemented for a while and when 
complete follow-up data were available for all patients with regard to 5-year survival. 
This study began in 2009; therefore, 2003 was the latest patient cohort we could use. 
The 1997-2000 period represents a time when adjuvant therapy began to be used for 
lymph node positive patients with colon cancer and a more systematic approach to 
preoperative radiotherapy was introduced.  
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To analyse 5-year mortality, this time span was divided into several time intervals. 
These time intervals were defined relative to each year post-surgery. In addition, the 
first year was subdivided in two intervals, 0–2 months and 3–12 months in order to 
have a measure of 60-day postoperative mortality. We chose to use 60 days rather 
than 30 days (which is more usual) for two main reasons. First, recent studies have 
shown an increased rate of death >30 days postoperatively compared to the general 
population, which may be related to improved perioperative care94 that extends the 
postoperative time interval in which there are deaths that may be related to surgery. 
Second, our dataset includes the date of diagnosis but not the date of surgery. To 
ensure the anonymity of the patients, the diagnosis was approximated as the first or 
the fifteenth of each month, whichever was nearest the date of diagnosis. 
Statistics 
Continuous variables were tested for normality. Non-normally distributed continuous 
variables were reported as median values as a measure of central tendency and 
compared by the Mann-Whitney U-test. Categorical variables were analysed by 
contingency tables and compared by the Chi-square test. Multivariable analysis was 
performed when appropriate by logistic regression analysis. P-values <0.05 were 
regarded as significant. 
Survival analysis  
Survival analysis was performed to address objectives 1 and 2 of the study. Survival 
is one of the most important outcome measures in cancer treatment. Because death 
may occur from causes unrelated to cancer, these other causes contribute to mortality. 
To compare treatment outcomes with regard to major changes in treatment guidelines 
at the national level as defined by objectives 1 and 2, information about cancer-
related deaths was considered essential. However, reliable information on the true 
cause of death was not available for all patients reported to the Norwegian Cause of 
Death Registry. The use of relative survival can compensate for this lack of 
information95. This method provides a measure of the deaths in a group of patients 
with a given disease by comparing the number of deaths in the patient group with a 
patient group matched for age and sex, the members of which are assumed not to 
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have the disease in question (colon or rectal cancer for our study). We calculated 
relative survival by matching the major demographic characteristics of the patients to 
subjects in the general population using the Norwegian population life tables as 
provided by Statistics Norway for the study period. Comparisons between groups 
were made using maximum likelihood estimates.96  
Notably, we compared the two groups in two time periods, i.e. 1994 –1996 and 2001–
2003. Life tables show that a 70-year-old in 2001 was expected to live 1.6 years 
longer than a 70-year-old in 1994. This is due to generally improved health in the 
population. Using relative survival corrects for this factor by comparing the patient 
group with members of the general population who were the same age at the same 
time as the patients. 
Excess hazard 
The mortality of patients, i.e. hazard to die, can be expressed as the hazard to die of 
the general population added to the hazard to die related to the disease, i.e. excess 
hazard. 
To estimate the excess hazards of patients with colon or rectal cancer during various 
time intervals in their 5-year follow-up periods (objective 2 of the study), we 
calculated the average rate of death over a time interval multiplied by the length of 
the time interval and then expressed this as the number of excess deaths per 1000 
patient-years.97 
The baseline excess hazard is often estimated as a stepwise function98 but can also be 
estimated as a smoothed function99. We used a stepwise baseline excess hazard. 
When we simultaneously reported excess hazard ratios for each time interval during 
the 5-year follow-up, we used a 1% level for the inference in each single time interval 
to guard against type 1 errors in multiple testing. This 1% level corresponds to the use 
of an overall 5% level with a Bonferroni correction for multiple testing. 
Statistical analysis was performed using the software package PASW Statistics 18.0 
for Mac (SPSS Inc., Chicago, IL, USA) R 2.9.2 (www.r-project.org) with the R-
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package “relsurv” was used for the relative survival calculations and excess hazards 
calculations.100  
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12. Results 
12.1 Paper I 
The first study included 19,053 patients who had undergone curative resection for 
colon or rectal cancer. The study showed an increase in relative survival from the 
1994–1996 period to the 2001–2003 period, both for colon cancer (73.8 vs. 78.0%, 
p<0.001) and rectal cancer (72.1 vs. 79.6%, p<0.001). However, when comparing 
patients with colon cancer and rectal cancer, there was significantly better relative 
survival for rectal cancer patients in the 2001–2003 period (p=0.03) while no 
difference in relative survival was observed in the 1994–1996 period. Improved 
relative survival in colon cancer patients was mainly seen in 2001–2003 in those with 
pN+ disease (50.7 vs. 62.1% for colon cancer and 47.6 vs. 67.2% for rectal cancer, 
respectively). While this was true only for colon cancer patients under 75 years i.e. 
those for whom adjuvant chemotherapy was recommended, relative survival 
increased in all age groups for rectal cancer.  
12.2 Paper II 
To investigate the differences in survival outcomes in patients with colon or rectal 
cancer, we studied the excess death at different time intervals after surgery for colon 
and rectal cancer patients during the time periods 1994–1996 and 2001–2003. A total 
of 11,437 patients who had undergone curative resection were included. 
For patients treated from 1994–1996, excess mortality was similar in colon and rectal 
cancer patients in all time intervals. For those treated in 2001–2003, excess mortality 
was significantly lower in rectal cancer patients than in colon cancer patients 
perioperatively (in the first 60 days: excess mortality ratio=0.46, p=0.007) and during 
the first 2 postoperative years (2–12 months: excess mortality ratio=0.54, p=0.010; 1–
2 years: excess mortality ratio=0.60, p=0.009). However, excess mortality in rectal 
cancer patients was significantly higher than in colon cancer patients during late 
follow-up, i.e. 4–5 years postoperatively (excess mortality ratio=2.18, p=0.003).  
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12.3 Paper III 
Paper III analysed the number of LNs harvested during curative resections for colon 
cancer and investigated the possible factors leading to poor harvest, which was 
defined as ≤8 LN. A total of 2,879 patients were included in the study. The median 
number of LNs harvested was 14. While 69.9% of the patients had adequate LN 
harvest (≥12 LNs), 14.4% had poor LN harvest. The factors that were analysed to 
determine whether they were associated with poor LN harvest included age group, 
sex, tumour characteristics, specimen characteristics and the use of the national 
pathology report template.  
Multiple logistic regression analysis showed that male sex, age >75 years, sigmoid 
tumours, pT category 1–2, failure to use the pathology report template and a distance 
of ≤5 cm from the tumour to the bowel resection margins were all independent 
factors for poor LN harvest. Age <65 years, pT category 3–4 and poor tumour 
differentiation were independent predictors of stage III, i.e. pN+, disease. An increase 
in the number of harvested LNs did not show a corresponding increase in stage III 
disease when we compared patients with ≤8, 9–11 and ≥12 harvested LNs. Moreover, 
use of the national report template was not associated with an increase in the 
proportion of patients with stage III disease. 
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13. Discussion 
This thesis analysed the impact of implementation of national guidelines on treatment 
outcomes of patients with cancer of the colon and rectum. Paper I demonstrated 
significant improvement in relative survival for patients with colon and rectal cancer 
undergoing curative surgery over a 10-year period. This improved survival emerged 
during time periods, i.e. from the 1994–1996 time period to the 2000–2003 time 
period, when new strategies for the management of patients with CRC were 
introduced and implemented at the national level. Notably, this survival increase was 
more predominant in patients with rectal cancer compared to colon cancer. Thus, at 
the end of the study period, the long-term survival of patients with rectal cancer had 
changed from being worse than for colon cancer patients to being better than for 
colon cancer patients.  
As far as we know, this is the first time this has been documented in the literature for 
patients undergoing curative treatment for CRC. We believe these results reflect the 
effects of systematic changes in disease management, with a major focus on rectal 
cancer. Implementation of treatment changes was mandatory and well documented by 
the NRCR.101 It is reasonable to think that the Norwegian health care system, which 
ensures that high quality health care is provided to the entire population, was an 
important factor for the implementation of guidelines and thus for the major 
improvements in patient outcomes. In the past, studies have reported a worse 
prognosis for rectal cancer patients compared to patients with colon cancer.102, 103 A 
recent study from Sweden showed that 5-year relative survival was similar for rectal 
and colon cancer.104 The same was found in a Dutch study, i.e. worse prognosis for 
rectal cancer in the past and later a catch-up for rectal cancer resulting in similar 
survival statistics105. However, these studies included patients with all stages of 
cancer, irrespective of treatment goals (i.e. curative vs. palliative) while the current 
study analysed CRC patients undergoing curative surgery. Our results are in line with 
the hypothesis that the focus on rectal surgery has resulted in measurably improved 
outcomes on a national level. 
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There is some question about whether these changes might be related to factors other 
than improved treatment. For example, one possible explanation for the results could 
be an earlier diagnosis in the 2001–2003 period compared to the 1994–1996 period. If 
this was the case, it would explain better survival in both groups, but it would not 
explain the difference between colon cancer and rectal cancer patients. We do not 
believe that this is the explanation as there was no CRC screening in either period, 
and, more importantly, there was a stage migration towards more patients with lymph 
node positive disease in the later period. In fact, this observation could be interpreted 
as meaning that the diagnosis was made later in the 2001–2003 period, not earlier. 
We think this is more likely the result of better staging rather than a true change in 
stage. Therefore we think that the observed improvement in survival is reliable and is 
due to changes in treatment. 
It is also important to ask whether the observed improvements in survival were the 
result of improved surgical technique (i.e. TME) for rectal cancer as compared to 
colon cancer or were due to other factors, such as better perioperative care, 
centralisation, chemotherapy or radiation. The effect of radiation on survival of 
patients with rectal cancer was reviewed in a Cochrane report that concluded that 
there was a 2% survival gain in the 5-year period after radiation106. However, this 
review included studies performed both before and after the TME surgery era. We 
think that the studies published prior to the TME era might skew the effect of 
radiation on survival towards falsely higher outcomes. Notably, a Dutch TME trial 
showed that patients randomised to preoperative radiation had a 50% lower 
probability of local recurrence, but survival was unchanged107. Moreover, only 9.7% 
of the rectal cancer patients in our study received radiotherapy. Accordingly, the use 
of radiation most likely is not the main explanation for the improved survival that we 
observed.  
The recommendation of adjuvant chemotherapy, which was the only major change in 
colon cancer treatment, was limited to lymph node positive patients ≤75 years old108. 
Interestingly, we did not see any survival effect in the patients with lymph node 
negative disease or in those patients with lymph node positive disease >75 years old. 
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Thus, the only increase in survival occurred in the group that were presumably given 
adjuvant chemotherapy. Therefore, we think that the increased survival in the colon 
cancer group was due mainly to adjuvant chemotherapy. Our findings are in line with 
a paper from the Netherlands in which a survival gain was seen for the youngest 
colon cancer patients but not in patients who were older than 75 years109. A recently 
published study also showed that the survival effect of adjuvant chemotherapy for 
patients >75 years is significant110. 
Paper II analysed possible differences in excess mortality between colon and rectal 
cancer patients with regard to specific time periods, age ≤ or > 75 years of age and 
lymph node status. The results did not show any significant survival difference for the 
first 60 days for either colon or rectal cancer. This contrasts with the findings of 
Mitry et al.111, 112 who claimed that the major improvement in survival for colorectal 
cancer is mostly due to better perioperative care. We found reduced mortality rates in 
the time intervals during later follow-up both for colon cancer and for rectal cancer. 
Interestingly, mortality rates for rectal cancer patients were significantly lower during 
the 3 first years of follow-up and then were significantly higher during the fifth year 
as compared to colon cancer patients. The excess mortalities translate into absolute 
numbers as follows: 2 patients out of 100 who were operated for colon cancer died 
the fifth year after surgery, but 4 patients out of 100 who were operated for rectal 
cancer died the fifth year. This is in contrast to the results of Engholm et al., who did 
not find any differences in mortality in the fifth year after surgery. However, that 
group studied the period 1999–2000 and included patients with all stages of cancers 
from several countries, whereas our study focused on patients who were curatively 
treated113.  
Our observation of increased perioperative survival and better survival during the 
first years of follow-up has several possible explanations, such as improved intensive 
care or centralisation of surgical services. An English study reporting on 30-day 
mortality for colorectal cancer found wide variations in mortality, from 3% to 16%, 
and they also found lower 30-day mortality for rectal cancer compared to colon 
cancer114. Another plausible explanation is that colon and rectal cancer patients 
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present differently with regard to acute admissions. Recent studies report emergency 
operations in 25% of colon cancer patients and in only 1–3% of rectal cancer 
patients.33, 115. Unfortunately, our data do not provide sufficient clinical data with 
regard to emergency vs. elective presentation. However, according to a recent single-
centre analysis in Norway, fewer emergency procedures were reported during early 
2000 compared with previous decades, which may point to a generally lower rate of 
patients with acute presentation of CRC.116 The findings from a Danish study are also 
notable in that they showed medical complications to be the main cause of early death 
after emergency surgery117. This underlines the importance of 24-hour availability of 
intensive care units, radiology and other services, which may be more accessible in 
larger hospitals. 
The finding of inversed mortality rates, i.e. better survival for colon cancer patients 
than for rectal cancer patients the fifth year after surgery, was surprising. To the best 
of our knowledge, this is the first report to describe this observation. The reason 
underlying the inversed mortality rates during the fifth year is unclear; however, we 
speculate that rectal cancer patients may experience more metastatic disease at the 
end of follow-up compared to colon cancer patients. According to the national 
guidelines, rectal cancer patients with pN+ disease should not receive adjuvant 
chemotherapy because of a lack of sufficient scientific evidence118, 119. This is not in 
line with findings of a recent Cochrane review, which reported a 17% reduced risk of 
death in rectal cancer patients treated with adjuvant chemotherapy120. A survival gain 
was also seen in a retrospective study in Sweden that investigated adjuvant 
chemotherapy for stage III rectal cancer110. In other words, the initial survival benefit, 
which is probably due to better control of the primary tumour, may be reduced or 
even inverted by later adverse events. Due to the use of relative mortality 
calculations, these finding are most likely related to either the disease or treatment. 
We hypothesize that increased distant spread at the end of follow-up may be the 
reason for this higher mortality. Our findings of lower mortality rates in patients with 
pN+ colon cancer aged ≤75 years, i.e. those receiving adjuvant chemotherapy, may 
support this theory. However, we have no data to verify this hypothesis. Further 
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research should focus on possible differences in late recurrences in colon and rectal 
cancer.  
 Papers I and II showed that based on better outcomes for rectal cancer patients 
after implementation of treatment guidelines, there should be similar efforts to 
determine how to improve the outcomes of patients with colon cancer. In this respect, 
it seems obvious to focus on the quality of surgery for colon cancer. One of the 
strongest predictors for outcome after curative resections for colon cancer has been, 
and continues to be, the presence of lymph node metastases, i.e. pN0 or pN+. The 
presence of lymph node metastases prompts a recommendation for adjuvant 
chemotherapy. Accordingly, lymph node harvest is considered to be the major quality 
indicator for colon cancer surgery. The internationally accepted number of lymph 
nodes that should be harvested is at least 12, although some dispute this number121.  
In Paper III, we studied lymph node harvest in a national cohort of patients curatively 
resected for colon cancer. The data from the NCCR demonstrated a high overall LN 
yield of a median of 14 LNs. Our observation that 69.9% of the patients had a LN 
harvest of ≥12 LN is notable as this is more LNs than have been reported recently 
reported in other national cohorts122-127. While most other studies focus on harvesting 
the highest possible number of LNs , we wanted to identify factors associated with 
poor LN harvest. Specifically, we wanted to identify both factors that might be 
amenable to change, and those that were inherent to the disease. We found that poor 
LN harvest (≤8 LNs) was associated with male gender, increasing age, pT stage 1–2, 
resection margin < 5 cm, failure to use the pathology template and sigmoid 
resections.  
These factors are discussed extensively in Paper III. Among the modifiable factors, 
both the surgeon and the pathologist are central in achieving adequate LN harvest. 
Surgeons should be aware that left-sided tumours, and in particular sigmoid cancers, 
need particular care in order to achieve both adequate resection margins and removal 
of sufficient LNs. Pathologists need to dissect meticulously to identify the largest 
possible number of nodes, possibly by using special fixating solutions. The number of 
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lymph nodes identified depends to a considerable extent on the pathologist, who must 
spend sufficient time and use agents that facilitate the identification of lymph 
nodes128, 129. Reese et al.130 showed that training an assistant to harvest lymph nodes 
increased the yield from a median of 13 to 19 LNs from one time period (1999–2002) 
to another (2003–2006). Recently, Fan et al.131 reviewed 334 CRC specimens for 
lymph nodes. They initially found 33.6% (122) of the patients had lymph node 
positive disease, but the review showed an additional 12 patients with stage III 
disease. This finding altered treatment in 14.8% of the patients. Moreover, 
considerable variations have been reported regarding the content and quality of 
pathology reports from different laboratories132. Some studies claim that use of a 
report template increases the LN harvest133, 134 and improves the reporting of other 
key parameters135, 136. This is supported by our results, which showed that use of the 
report template was significantly associated with higher LN retrieval. Whether this 
difference is related solely to better reporting, or the ability to implement the national 
template as a proxy for high standard of pathological work is hard to say. However, 
the detection of patients with pN+ disease was not affected. 
In addition to technical factors, the possible importance of tumour biology in LN 
retrieval has gained more attention. The finding of more lymph nodes on the right 
side of the colon may imply that that the surgery is better or that more tissue is 
removed, but it may also suggest that there are differences in tumour biology at 
different tumour sites. Different pathways of tumourigenesis in various parts of the 
bowel have been addressed and identified, including chromosome instability and 
microsatellite instability (MSI). A greater proportion of right-sided colon cancers are 
associated with MSI28. MSI, which is present in roughly 20–25% of right-sided colon 
tumours, has also been associated with a higher number of loco-regional LNs, which 
might contribute to a greater LN yield28, 137.  
It is important to emphasize that the number of lymph nodes needed for adequate 
staging remains controversial138. Parsons et al. conducted a large study in the US that 
showed a gradual increase in the number of nodes removed over the course of two 
decades; however, there was no corresponding increase in the proportion of pN+ 
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disease139. That study found a node positivity rate of close to 40%. A Swedish study 
found the same thing: there was a steady increase in the median lymph node harvest, 
from 7 lymph nodes in 1996–1999 to 18 in 2005–2009140. In this study, they found a 
node positivity rate of 41.9%, 40.9% and 41.6% in the three time periods that they 
looked at. This indicates that there might be a critical threshold of LNs that must be 
harvested. Beyond this number, further increase does not substantially increase the 
proportion of patients with pN+ disease. This is disputed by researchers who report a 
relationship between increased survival and increased lymph node harvest126, 141-143. 
These apparent differences may stem from the designs and methods of the various 
studies. While studies favouring extensive LN harvest are based mostly on results 
from institutional data64, those indicating a threshold number for optimal LN harvest 
(without an increase in pN+ disease beyond that threshold) are based mostly on data 
from large national databases126, 139. Accordingly, a fixed number for LN harvest as a 
measure of quality should be used with caution and should take into account both 
factors that are amenable to change as well as factors that are. 
All three studies in this thesis have a number of limitations. Every study based on 
data from a large registry is limited in terms of the type and quality of the 
registration. For the first two papers, we had the patients’ date of diagnosis but not 
the date of surgery. It is reasonable to suppose that for most of the patients, the time 
interval from diagnosis to surgery was limited, perhaps on the order of 2–6 weeks. 
However, patients with rectal cancer who received radiation preoperatively had a 
longer time to surgery, i.e. about three months. This might have some influence on 
data in the first follow-up time interval (i.e., 60-day data; Paper II). On the other 
hand, this was true for only a small proportion of patients (8% and 18% in the two 
periods, respectively). Further, we do not know whether all patients with colon cancer 
and pN+ disease actually received adjuvant chemotherapy: our analyses were based 
on the assumption that recommendations to offer this treatment to patients ≤75 years 
with pN+ disease were followed. However, we have reason to believe that this was a 
good assumption as there is a strong tradition of adherence to national directives in 
the health care system in Norway.  
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Further, the real golden standard of the number of lymph nodes needed to correctly 
identify all patients with pN+ disease remains unknown. If few LNs are reported, we 
do not know whether this is due to the surgeon or the pathologist or even due to the 
patient. When large volume hospitals are compared with lower volume hospitals, we 
have to assume there is a selection bias regarding which patients are treated where. 
When comparing different time periods, we found that fewer patients were offered 
curative resections in the 2001–2003 time period, suggesting better preoperative 
workup and selection. This may lead to increased survival according to the Will 
Rogers phenomenon144: exclusion of patients with metastatic disease confers by itself 
a better prognosis in the group of patients who are thought not to have metastases. 
Studying total survival without excluding those who were not operated and those with 
metastases could have avoided the latter. However, since our intent was to study the 
influence of implementation of national guidelines on patients operated with curative 
intention and on the quality of surgery, this possible source of error could not be 
avoided. 
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14. Conclusions 
Increased attention on the management of colorectal cancer has been worthwhile. 
First, the focus on rectal cancer improved survival, which is currently even better 
than that of colon cancer. Secondly, adjuvant chemotherapy for lymph node positive 
patients in colon cancer seems advantageous. However, improvement of survival for 
patients with pN+ colon cancer > 75 years of age is lacking.  
We found that mortality rates for colon and rectal cancer differed for various time 
intervals during the 5-year follow-up period. Even though colon cancer patients had 
higher excess mortality for the first years after surgery, the mortality rate of patients 
with rectal cancer was twice that of colon cancer patients during the 5th year of 
follow-up. 
LN harvest is supposed to be a quality indicator of colon cancer surgery. The analysis 
of LN harvest in our national cohort of patients curatively treated for colon cancer 
showed that there are a number of factors associated with low LN harvest. While 
some of those factors could be modified by appropriate measures, such as optimizing 
surgery, pathological evaluation of the specimen and reporting, other factors related 
to the patient and tumour characteristics are not amenable to change. Optimal LN 
retrieval and evaluation remains an important objective in surgical treatment for 
curing colon cancer, but these factors have to be taken into account when using LN 
harvest as a measure of the quality of surgery.  
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15. Future perspectives 
Our study revealed that patients with rectal cancer had better survival than patients 
with colon cancer after implementation of national guidelines focusing on this 
disease. This finding implies that there is a strong need to direct more attention to 
colon cancer. According to the results of Paper I, the subgroup of patients with pN+ 
disease >75 years of age who were not receiving adjuvant chemotherapy was a 
subgroup that did not show improved survival. This may indicate that treatment 
recommendations for those patients are suboptimal, and more research is needed to 
improve  treatment for patients >75 years with pN+ colon cancer. 
The finding of a doubled mortality rate in curatively treated patients with rectal 
cancer compared to colon cancer during the 5th year of follow-up is troublesome. 
Further research is needed to identify the possible causes, which may be related to the 
treatment or to the disease, such as late local recurrences or metastatic disease. Our 
data did not allow any conclusions to be drawn regarding the reason(s) for this 
difference. We hypothesise that metastases that occur during late follow-up may be 
one possible cause. If this hypothesis is confirmed, there may be a reason to 
reconsider adjuvant treatment recommendations with regard to adjuvant 
chemotherapy for rectal cancer patients with pN+ disease. 
Regarding surgery for colon cancer, some new approaches to surgical treatment have 
been promoted recently, such as complete mesorectal excision (CME), which is 
analogous to the concept of TME for rectal cancer. While a number of institutional 
reports are promising, it is unclear whether this concept can be applied to colon 
cancer the way that TME applies to rectal cancer. Our study raises the question of 
whether there is the need to revisit the number of hospitals that offer curative surgery 
for colon cancer in Norway: For colon cancer, the number has remained unchanged at 
about 50 hospital, compared to the slightly less than 30 hospitals that treat rectal 
cancer. A re-evaluation of the hospitals that provide curative surgery for colon cancer 
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requires additional and clearer outcome measures than just LN harvest, such as 
surgical complications and survival. 
Finally, a number of new health technologies have emerged in recent years, such as 
robotic-assisted surgery, single port laparoscopic surgery and the principle of natural 
orifice transluminal endoscopic surgery (NOTES). Careful health technology 
assessment that is guided by relevant outcome measures must be the unconditional 
prerequisite to ensure the safe introduction of new surgical approaches that will 
maximise the benefits of surgery for patients with cancer of the colon and rectum. 
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16. Appendix 
Registration form for solid tumours. Cancer Registry of Norway, main database 
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Registration form, Norwegian Rectal Cancer Registry, 1993 – 2006  
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Registration form, Norwegian Colorectal Cancer Registry, from 2007 - 2012 
 
 
5. SYKDOMSUTBREDELSE VED DIAGNOSE
Utførte undersøkelser (basis for diagnostikk)
Levermetastaser ż Nei ż Ja ż Mistenkt Ƒ Ultralyd Ƒ CT Ƒ MR Ƒ Ingen
Lungemetastaser ż Nei ż Ja ż Mistenkt Ƒ Rtg thorax Ƒ CT Ƒ MR Ƒ Ingen
 .lkni( resatsatem nrejf erdnA
)esotam onicrac .tirep
ż Nei ż Ja ż Mistenkt Ƒ Ultralyd Ƒ CT Ƒ MR Ƒ Ingen
Hvis ja, hvor: CEA:
Dybdevekst av tumor i
diomgisotcer go mutcer
ż I tarmvegg (T1-T2)
ż Gjennom tarmvegg (T3) Ƒ Ultralyd Ƒ CT Ƒ MR Ƒ Ingen
ż Innvekst naboorgan (T4)
Antatt CRM |__|__| mm Antatt positive lymfeknuter  ż Ja  ż Nei   ż Ikke utført
1. PASIENT/BEHANDLINGSINSTITUSJON
Fødselsnr   |__|__|__|__|__|__|__|__|__|__|__| Institusjon .......................................................................................
Fornavn ........................................................................................... Avdeling .........................................................................................
Etternavn ……………………………………......................................... ż Innlagt   ż Poliklinisk     Dato    |__|__|__|__|__|__|             
Postnr    |__|__|__|__|      Poststed ……………………........……...... Utskrevet ż I live   ż Død 
2. MELDINGSTYPE (bare ett kryss)
ż Primær tumor ż Residiv*   Dato    |__|__|__|__|__|__| ż Metastase*   Dato    |__|__|__|__|__|__|
ż Obduksjon**   Dato    |__|__|__|__|__|__|
4 tknup tu nuk llyF* *   5 tknup lit åG *
3. SYKDOMSTEGN OG DIAGNOSTIKK
Hadde pasienten symptomer? ż Ja   ż Nei     Symptomdebut (måned/år)   |__|__|__|__|
Arvelig predisposisjon ż Ja     ż Nei    
Colo/rectoskopi ż Ja, tumor sett ż Utført, tumor ikke sett ż Ikke utført
Rtg colon ż Ja, tumor sett ż Utført, tumor ikke sett ż Ikke utført
CT-abdomen ż Ja, tumor sett ż Utført, tumor ikke sett ż Ikke utført
Colograﬁ (CT) ż Ja, tumor sett ż Utført, tumor ikke sett ż Ikke utført
Klinisk undersøkelse alene ż Ja, sikker tumor
Biopsi av tumor ż Ja ż Nei Pat. lab ............................ Diagnosetidspunkt    |__|__|__|__|__|__|
4. TUMORS LOKALISASJON
Tumors lokalisasjon (Hvis ﬂ ere, kryss av for de aktuelle)
Ƒ Appendix Ƒ Cøkum Ƒ Ascendens Ƒ Høyre ﬂ eksur
Ƒ Transversum Ƒ Venstre ﬂ eksur Ƒ Descendens Ƒ Sigmoideum (≥ 20 cm)
Ƒ Rectosigmoid (16–< 20 cm)     Ƒ Rectum (< 16 cm fra analåpning på stivt skop)   ...................... cm
                                                                          Målt ved MR: øvre kant av m. puborektalis til nedre kant av tumor ............. cm
6. FORBEHANDLING
Ƒ Ingen        Ƒ Strålebehandling        Ƒ Kjemoterapi        Ƒ Radiokjemoterapi        Ƒ Avlastende stomi        Ƒ Stenting
ĺ
ĺ
ĺ
ĺ
MELDING TIL COLORECTALCANCERREGISTERET
Svulster i colon/rectum – skjema i kraft fra 01.01.2007
Kreftregisteret, Postboks 5313 Majorstuen, 0304 Oslo
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